MM-192 Preliminary Recommendations for Prevention and Management of Infections, Hypogammaglobulinemia, and Neutropenia During Treatment With Teclistamab Based on Experience From the MajesTEC-1 Study
Salomon Manier(Université de Lille), Niels W.C.J. van de Donk(Oncode Institute), Cesar Rodriguez(Wake Forest University), Keqin Qi(Janssen (United States)), Rachel Kobos(Centre Hospitalier Universitaire de Nantes), Raluca Verona(Centre Hospitalier Universitaire de Nantes), Arnob Banerjee(Johnson & Johnson (United States)), Thomas G. Martin(University of California San Francisco Medical Center), Margaret Doyle(Janssen (Ireland)), Ajay K. Nooka(Emory University), Katherine Chastain(Janssen (United States)), María‐Victoria Mateos(Hospital Clínico San Carlos)
Cited by 2
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k